Insulet Corporation $PODD Shares Bought by Aster Capital Management DIFC Ltd

Aster Capital Management DIFC Ltd grew its holdings in shares of Insulet Corporation (NASDAQ:PODD) by 1,015.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,979 shares of the medical instruments supplier’s stock after buying an additional 2,712 shares during the period. Aster Capital Management DIFC Ltd’s holdings in Insulet were worth $920,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in PODD. True Wealth Design LLC raised its stake in Insulet by 288.0% during the 3rd quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 72 shares in the last quarter. Golden State Wealth Management LLC increased its holdings in shares of Insulet by 202.9% during the second quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock valued at $32,000 after purchasing an additional 69 shares during the period. Whittier Trust Co. of Nevada Inc. increased its holdings in shares of Insulet by 48.9% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 131 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 43 shares during the period. Quent Capital LLC bought a new stake in shares of Insulet during the third quarter valued at about $49,000. Finally, Osterweis Capital Management Inc. acquired a new stake in Insulet in the second quarter worth about $51,000.

Insider Activity at Insulet

In other news, Director Michael R. Minogue bought 2,030 shares of the firm’s stock in a transaction on Wednesday, February 25th. The stock was bought at an average cost of $246.23 per share, for a total transaction of $499,846.90. Following the completion of the acquisition, the director directly owned 17,483 shares in the company, valued at $4,304,839.09. This represents a 13.14% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. 0.39% of the stock is currently owned by insiders.

Insulet Stock Performance

PODD opened at $251.50 on Friday. The company has a quick ratio of 2.15, a current ratio of 2.81 and a debt-to-equity ratio of 0.61. The firm has a market cap of $17.71 billion, a PE ratio of 71.86, a P/E/G ratio of 1.48 and a beta of 1.41. The business has a fifty day simple moving average of $269.07 and a 200-day simple moving average of $303.58. Insulet Corporation has a fifty-two week low of $230.05 and a fifty-two week high of $354.88.

Insulet (NASDAQ:PODD) last announced its earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 EPS for the quarter, beating the consensus estimate of $1.48 by $0.07. The business had revenue of $783.80 million during the quarter, compared to the consensus estimate of $768.31 million. Insulet had a return on equity of 24.90% and a net margin of 9.12%.Insulet’s revenue was up 31.2% compared to the same quarter last year. During the same period in the prior year, the business posted $1.15 earnings per share. As a group, equities analysts predict that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Stifel Nicolaus lowered their target price on shares of Insulet from $370.00 to $350.00 and set a “buy” rating on the stock in a research note on Wednesday, February 4th. Canaccord Genuity Group decreased their price objective on shares of Insulet from $450.00 to $435.00 and set a “buy” rating for the company in a report on Wednesday, February 18th. Jefferies Financial Group boosted their target price on Insulet from $375.00 to $400.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Citigroup cut their target price on Insulet from $380.00 to $345.00 and set a “buy” rating for the company in a research report on Thursday, February 19th. Finally, Royal Bank Of Canada increased their price target on Insulet from $370.00 to $380.00 and gave the company an “outperform” rating in a research note on Friday, November 21st. Twenty investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $354.57.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.